Excitatory and inhibitory neurons are differentially vulnerable to tau pathology in primary and secondary affected regions of EC-tau mice. Tau species recognized by human-specific antibodies such as MC1 (which targets misfolded tau) were co-localized with EX neuronal markers (TBR1 and SATB2), but there was almost no co-localization with IN neuronal markers (PVALB, SST, and CALB2) in layers II-IV of the medial entorhinal cortex (MEC), perirhinal cortex (PRH), and neocortex ( 
N eurodegenerative disorders are characterized by the accumulation of pathological proteins and the progressive loss of specific neuronal cell populations. The accumulation of misfolded tau aggregates is a defining feature of Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD) linked to tau [1] [2] [3] . Several types of neurons have been reported to be particularly vulnerable in AD [4] [5] [6] [7] [8] [9] , Down's syndrome 10 , and FTLD 2, 3, 11 . The distribution of neurons vulnerable to tauopathy follows a sequential pattern that suggests that cell populations in different regions of the brain are selectively at risk. More specifically, the morphology and location of cells within the entorhinal cortex (EC) and hippocampus that accumulate tau and degenerate in the earliest stages of AD suggest that excitatory (EX) neurons are preferentially impacted 4, 12 . Previous studies have addressed the question of why putative EX neurons could be particularly vulnerable to degeneration in aging, AD, and other neurodegenerative disorders 6, [13] [14] [15] . Determinants of neuronal vulnerability might include cell size and location within neural circuits, signaling pathways controlling excitation, mechanisms regulating calcium and energy homeostasis, metabolism of disease-specific proteins, repertoires of signal-transduction pathways and stress-resistance mechanisms, and protein homeostasis dysfunction [16] [17] [18] [19] . However, the exact molecular determinants underlying the selective vulnerability of EX neurons to tau pathology have not been established.
To explore these determinants, we employed four complementary approaches. First, using a series of cell-type-specific markers on AD patient brains and a mouse model of tauopathy 20 , we showed that tau co-localizes predominantly with EX, compared to inhibitory (IN), neuron markers, not only in the EC but also in areas affected later in the disease such as the neocortex 4 . Second, using singlenucleus RNA-seq datasets from normal donors, we identified a substantial difference between EX and IN neurons in genes involved in a branch of the protein homeostasis system that modulates the aggregation and clearance of tau. Third, using the weighted gene co-expression network analysis, we identified that BAG3, a putative aggregation protector 21, 22 , is a hub gene in the co-expression network relevant to tau homeostasis. Lastly, we confirmed that BAG3 is differentially expressed in human EX and IN neurons in non-AD and AD brains and that it impacts tau accumulation in primary neurons. Taken together, these results support the conclusion that tau homeostasis contributes to the selective regional vulnerability of EX neurons to tau pathology and cell loss that defines AD, and they suggest that dysregulation of specific branches of the protein homeostasis system plays an important role in the initiation and spread of tau pathology in AD and the primary tauopathies. + tau with neuronal marker-positive neurons, quantified in the MEC, PRH, and NC (layers II-IV) of EC-tau mice at 22 and 30+ months (***P < 0.0001 vs. PVALB, SST, and CALB2 in mice matched for brain region and age; Kruskal-Wallis statistics: 53. 16 ). Data are presented as mean ± s.e.m. In c, d, f, n = 6 animals, 2 sections per animal; sections with no MC1 + neurons were removed from further analysis, for example, PRH 22 months: n = 9; PRH 30+ months: n = 11; NC 22 months: n = 6; NC 30+ months: n = 11 independent sections); in e, n = 7 independent experiments and each value is the average of 12 biological independent sections. Statistical significance was assessed by Kruskal-Wallis test with Dunn's multiplecomparison test (c) and one-way ANOVA with Tukey's post test (d). In e, f, statistical significance was assessed by two-tailed unpaired t test.
either 22 or 30+ months of age (Fig. 1a-c and Supplementary Fig. 1 ). These results are consistent with the observation of limited colocalization of human tau with IN neurons in the dentate gyrus of this mouse model 23 . In addition to being differentially vulnerable to pathological tau accumulation, EX neurons in the MEC were also differentially vulnerable to cell loss. The number of EX neurons was significantly reduced in the MEC, but not in the PRH or NC regions of EC-tau mice at 30+ months compared with 22 months (Fig. 1d) . However, there was no significant difference in the number of IN neurons in EC-tau mice at 30+ months compared with 22 months (Fig. 1d) . The number of MC1 + neurons was also significantly reduced in the MEC of EC-tau mice at 30+ months compared with 22 months (Fig. 1e) , most likely due to the dramatic loss of EX neurons in that region (Fig. 1d) . There was no significant difference in the number of EX neurons in nontransgenic (wild-type) mice between 22 months and 30+ months (Fig. 1f) , indicating that the loss of EX neurons was not associated with aging but with the maturation of tau pathology in the MEC. The increased number of MC1 + neurons in the PRH and NC of EC-tau mice at 30+ months (Fig. 1e) indicates that the propagation and spreading of tau pathology from the primary to the secondary affected areas of the neocortex. Taken together, these results demonstrate that EX neurons are vulnerable to both the accumulation and the propagation of tauopathy in this mouse model of tauopathy.
EX and IN human neurons are differentially vulnerable to tau pathology in primary and secondary affected regions of AD brain. To explore whether or not pathological tau also differentially impacts human EX neurons in AD, we performed co-localization studies on postmortem brain tissues at different stages of AD, as assessed by the Braak staging protocol 4 . Consistent with the mouse data, we found that MC1 + tau pathology was mainly co-localized with EX neuronal markers, but not IN neurons in layers II-IV of the EC and in secondary affected regions such as the prefrontal cortex (Brodmann area 9, BA9) at early and late Braak stages (Fig. 2a-c and Supplementary Fig. 2) . Moreover, the numbers of EX neurons were significantly reduced in the mid-to late-stage AD brain (Braak stages III-IV and V-VI) compared with non-AD controls (Braak stages I-II; Fig. 2d,e) . Tau pathology was not evident in microglia (IBA1 + ) or astrocytes (GFAP + ). The co-localization of pathological forms of tau with neuronal markers in both EC-tau mice and human AD was further confirmed with phosphorylation-site-specific tau antibodies. Consistent with the MC1 data, we found that EX neurons (SATB2 + ), but not IN neurons (GAD1 + ), co-localized with phospho-tau-specific antibodies, including AT8 (Ser202-Thr205), PHF1 (Ser396-Ser404), pS422-Tau (Ser422), and AT100 (Thr212-Ser214; Supplementary Fig. 3 ). Overall, these data suggest that in human brains, EX and IN neurons are differentially vulnerable to tau pathology in primary and secondary affected regions in AD. This conclusion is also consistent with previous reports of the selective vulnerability of pyramidal neurons in AD 4, 6, 12 .
Single-nucleus RNA-seq analysis reveals a specific tau homeostasis signature in EX neurons in the human brain. We hypothesized that the selective vulnerability of EX neurons to tau pathology could be determined by an intrinsic difference in the cellular environment T r a n s c r i p t o m e T r a n s c r i p t o m e T r a n s c r i p t o m e T r a n s c r i p t o m e T a n g l e s T a n g l e s T a n g l e s T a n g l e s [4] [5] [6] and corrected with a Benjamini-Hochberg multiple-hypothesis-testing correction (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Subproteomes (n sns and n drnc are the sample sizes for SNS and DroNc-Seq datasets, respectively: EX markers, n sns = n drnc = 2; promoters, n sns = n drnc = 6; MS (a subset of highly expressed and aggregation-prone proteins, which are supersaturated-i.e., proteins whose concentration in the cellular environment is higher than a critical value keeping them soluble and functional-and downregulated in AD):, n sns = 162, n drnc = 179; whole transcriptome (here reported as a negative control); tangles (proteins co-aggregating with tau and found in neurofibrillary tangles), n sns = 57, n drnc = 68; protectors, n sns = n drnc = 6; IN markers, n sns = n drnc = 3).
in terms of the specific branch of the protein homeostasis system that regulates tau aggregation. To test this idea and to begin to identify this 'tau homeostasis system' , we analyzed two independent single-nucleus RNA-seq datasets (SNS and DroNc-Seq) obtained from postmortem brain tissues of healthy adults without AD pathology 24, 25 . We found that the mRNA levels of genes encoding the proteins making up a metastable subproteome (MS) 26 , tau co-aggregators, and tau aggregation promoters 19 were increased, but the mRNA levels of tau aggregation protector genes 19 were decreased in EX neurons compared with IN neurons. Furthermore, differential expression of the tau homeostasis genes was seen in regions affected early (BA21, including EC; BA22, BA10, and BA41; and hippocampus) and late (BA17 and BA9) in AD ( , and (f) oligodendrocytes (ODC1, ODC2). For each bar, the significance was evaluated by building a null model for each subproteome and corrected with a Benjamini-Hochberg multiple hypothesis testing correction; *P < 0.05, **P < 0.01, ****P < 0.0001 (see Methods, Supplementary tau homeostasis (tau aggregation promoters and protectors and tau co-aggregators) and proteins in the MS were differentially regulated in cells that are vulnerable to tauopathy compared to those that are resistant to it. Taken together ( Supplementary Fig. 6 ), these results indicate that dysregulated tau homeostasis is closely linked to the etiology of tauopathy.
Glial cells have higher levels of aggregation protectors than neurons.
We observed that the subproteomes most relevant to tau homeostasis showed a specific signature for neurons compared to glial cell types (microglia, oligodendrocytes, and astrocytes). Overall, we observed statistically significant increases in mRNA levels of genes protecting from tau aggregation in glia cells, combined with relatively low expression of tau and low mRNA levels of genes promoting tau aggregation and encoding its co-aggregators ( Fig. 4 and Supplementary Table 2 ). These data were consistent with the observation that glia cells in the AD brain did not accumulate detectable levels of pathological tau ( Supplementary Fig. 2 ).
BAG3 is a hub gene in the co-expression network relevant to tau homeostasis. To identify a key master regulator responsible for modulating tau aggregates among the subproteomes linked to tau homeostasis, we performed a co-expression network analysis 27 on the SNS dataset. This type of analysis quantifies the covariation of genes within given samples or brain regions (cell types in our case) by measuring a quantity of reference, such as the Pearson's correlation coefficient. In this network, each gene is represented by a node and the co-expression values correspond to the weights associated with each link connecting two nodes. Although more complex approaches are possible 27 , a direct way to identify the hub genes that are central in the network is to sum the weights of all the links connected to a gene, which is defined as the total degree of a node. When the top 10% of the genes in the higher degree were isolated (Fig. 5) , the only gene belonging to both the protector subproteome and to the top 10% of the most co-expressed genes was BAG3. All the other genes belonged either to the MS or to the tangles, and no gene belonging to the promoter group was found among the hub genes (Supplementary Table 3 ).
Validation of the localization and expression levels of representative tau homeostasis signature genes by single-molecule FISH in human EC and prefrontal cortex. We next validated the results of the single-nucleus RNA-seq analysis of several AD-related genes, including MAPK1 (tau co-aggregators), FKBP5 (tau aggregation promoter), ENC1 (MS), and MAPT (the gene encoding tau) using a single-molecule RNA fluorescence in situ hybridization assay. The mRNA levels of MAPK1, FKBP5, and ENC1 were significantly higher in EX neurons than in IN neurons in both EC and BA9, while there was no significant difference in the mRNA levels corresponding to MAPT (Fig. 6) . These results support the conclusion that in vulnerable regions, EX neurons exhibit a cellular environment more conducive to tau aggregation and susceptibility to tau homeostasis dysfunction than IN neurons.
Validation of BAG3 protein levels in IN neurons and EX neurons of unaffected and AD brain tissue. To validate whether the protein level of one of the genes identified by the RNA analysis was differentially regulated between IN and EX neurons, and whether this was seen in both unaffected (non-AD) and AD brains, we examined the levels of BAG3 by immunofluorescence staining in the BA9 region of postmortem human tissue. BAG3 levels in NeuN + neurons labeled with the IN cell marker GAD1 (GAD1 + NeuN + ) were significantly higher in both non-AD and in AD neurons than in GAD -NeuN + neurons (P < 0.001, Supplementary Fig. 7 ). These cells were presumed to be mostly EX, as the great majority of GAD -NeuN + neurons co-labeled with EX neuron markers (data not shown).
Of note, the level of BAG3 protein was much higher in non-neuronal cells (NeuN -cells) than in neurons (NeuN + cells; Supplementary  Fig. 7a ). These results are consistent with our findings of almost no accumulation of pathological tau in IN neurons and glial cells.
Modulating the expression of BAG3 affects tau accumulation in primary cortical neurons. To further validate our results and confirm that genes identified through the bioinformatics analysis can contribute to the vulnerability of neurons to tauopathy, we manipulated the mRNA levels of BAG3, a master regulator gene and one of the major tau aggregation protectors associated with tau homeostasis 21 that was enriched in inhibitory neurons (Supplementary Table 1 ). BAG3 was of particular interest as it interacts with the co-chaperone HSPB8, which was also more highly expressed in IN neurons than in EX neurons (Supplementary Table 1 ). We found that knockdown of BAG3 using short hairpin RNA (shRNA) lentivirus in primary neurons from wild-type mice ( Fig. 7a and Supplementary Fig. 11 ) induced accumulations of endogenous tau recognized by the 12E8 antibody, mainly in neurites (Fig. 7b,c ; P < 0.01). In primary neurons expressing tau RD-P301S-YFP (an FTLD-causing mutation), knockdown of BAG3 led to an accumulation of tau in both cell bodies and neurites ( Fig. 7d-f ; P < 0.01). Overexpression of BAG3 significantly attenuated tau accumulation in EX neurons (Fig. 7d,e ; P < 0.01). There was a trend toward decreased tau accumulation in IN neurons where BAG3 was overexpressed, but the data did not reach significance ( Fig. 7f ; P = 0.098), most likely due to the very low level of tau aggregates in IN neurons in general. These results support our conclusion that genes associated with tau protein homeostasis contribute to neuronal vulnerability to tau pathology. 
Discussion
Understanding the molecular origins of selective cellular vulnerability is of fundamental importance for all neurodegenerative diseases 28 . Unfortunately, the molecular determinants of selective vulnerability have so far remained unclear, in part because we lack sufficient information on the molecular makeup of subpopulations of cells that are compromised in a particular brain region, by a particular protein, and in a particular disease. In this study, we addressed this problem with regard to tau using a mouse model of tauopathy, as well as human AD brains at different Braak stages. The EC-tau mouse model 20, 29 demonstrates progressive tauopathy that originates in the hippocampal formation but spreads to extrahippocampal and neocortical areas with age 30 . Because the model showed spread of the pathology, we were able to dissociate primary vulnerability from secondary vulnerability that occurred as a result of non-cell-autonomous tauopathy propagation. Primary vulnerability was seen in MEC neurons, which developed tau pathology early, whereas secondary vulnerability was seen in PRH and NC neurons, which developed pathology much later. We demonstrated that tau aggregates predominantly accumulated in EX neurons compared to IN neurons, not only in the primary affected region but also in secondary regions, suggesting that EX neurons were vulnerable to both cell autonomous and non-cell-autonomous accumulations of tau as tauopathy propagates.
Previous studies have explored why putative EX neurons could be particularly vulnerable to degeneration in AD and other neurodegenerative disorders 6, [13] [14] [15] . However, mechanisms underlying selective vulnerability of EX neurons to tau pathology have not been identified and tested. Our approach to answering this question was prompted by recent observations that age-related stress and dysfunction of protein homeostasis are observable in vulnerable neurons in aging and age-related neurodegenerative diseases 14, [16] [17] [18] . In particular, a transcriptional analysis of healthy brains at ages well before the typical onset of AD identified a protein homeostasis signature associated with protein aggregation and predicted the Braak staging of AD 19 . The protein homeostasis signature included a set of aggregation-prone proteins (MS) 26 and three other sets of protein homeostasis components (co-aggregators, aggregation promoters, and aggregation protectors) 18 . The overall relative expression of the protein homeostasis signature was elevated substantially in neurons compared with other cell types, indicating that neurons have a cellular environment most conducive to protein aggregation compared to other brain cell types 19 . Based on these results, we hypothesized that an intrinsic difference in the tau homeostasis system could contribute to the selective vulnerability of EX neurons to tau pathology. After analyzing two independent single-nucleus RNA-seq datasets from healthy donors, we showed that EX neurons are characterized by elevated expression a, Representative western blot images of primary cortical neurons transduced with lentivirus expressing scrambled BAG3, short hairpin BAG3 (shBAG3), or overexpressed BAG3 (OE), as described in Methods. GAPDH is a housekeeping protein used as the loading control. Three independent experiments were repeated with similar results. Full length blots can be found in Supplementary Fig. 11 . b, The percentages of EX and IN neurons (n = 55 from 11 coverslips per group) with 12E8 (pS262 and/or pS356 tau)-positive puncta (≥ 5) in the neurites were quantified as described in Methods (data are presented as mean ± s.e.m.; nonparametric Kruskal-Wallis test with Dunn's post hoc multiple-comparisons test; ***P < 0.0001 vs. neurons transduced with scrambled BAG3; Kruskal-Wallis statistic = 34.54). c, Representative immunocytochemical images of 12E8 + (red) puncta (white arrowheads) in the neurites of TBR1 + (green) EX neurons. White arrow, neuron with high TBR1; yellow arrow, neuron with low TBR1. GAD1 + (purple) IN neurons were also transduced with shBAG3 and tau was shown to accumulate in neurites (white arrowheads). Three independent experiments were repeated with similar results. Scale bars, 50 µ m. of a specific subset of aggregation-prone proteins (the MS) and tau aggregation promoters, as well as by decreased expression of tau aggregation protectors. These findings suggest that the selective vulnerability of EX neurons to tau aggregation, particularly in regions of the brain that are affected early on in AD, could be due to the intrinsic susceptibility of EX neurons to dysregulation of the branch of the protein homeostasis system that regulates tau aggregation. Since there are currently only two publicly available singlenuclei RNA-seq datasets from postmortem human brain tissue and they do not contain the exact same regions of the brain, we could not compare region-matched datasets. However, we still found that tau homeostasis gene signatures differed between EX and IN neurons in early and late affected region, even though the regions considered were not the same.
This idea is supported by the finding of relatively high expression of tau aggregation protectors in IN neurons and other cell types, such as microglia, that are resistant to pathological tau accumulation, in agreement with previous findings 19 . Differential regulation of several of the genes was validated at the mRNA level, and the protein level of BAG3, a master regulator belonging both to the 'protectors' subproteome and to the top 10% of most co-expressed genes, was shown to be substantially higher in IN neurons than in putative EX (GAD -NeuN + ) neurons in both non-AD and AD cases, supporting our finding that tau did not accumulate in IN neurons in AD brains. Furthermore, when we attenuated the level of BAG3 in primary neurons, the vulnerability of the cells to tau accumulation was substantially enhanced. As the promoter used to drive expression of the BAG3 shRNA or cDNA is not specific for neuron types, BAG3 mRNA was modulated in both EX and IN neurons. We expected the levels of tau to be attenuated in both EX and IN neurons in response, as our RNA data had shown that the gene is differentially, not selectively, regulated between the two neuron types, but it was noteworthy to observe that when BAG3 expression was reduced, tau accumulated in GAD + IN neurons. We have only very rarely observed tau accumulating in IN neurons in mouse or human studies. Conversely, vulnerability was reduced in neurons when BAG3 was overexpressed. These data confirm that the gene was impactful in IN neurons.
Our results indicate that neurons (and EX neurons in particular) represent a cellular environment more vulnerable to pathological tau accumulation compared to glial cell types, which is consistent with the finding that tau does not accumulate appreciably in glia in the AD brain. However, tau has been shown to accumulate in glia (tufted astrocytes and oligodendrocytes) in some but not all of the primary tauopathies [31] [32] [33] . Why tau should accumulate in glia in some tauopathies is not known, but from our results we suggest that it likely results from a combination of different forms of tau in different tauopathies and the sets of homeostasis genes in each cell type that control their likelihood to accumulate.
Our results are consistent with the known effects of impaired protein homeostasis on pathogenesis in age-related neurodegenerative diseases 14, [16] [17] [18] . Our findings characterize a subset of proteins that are highly specific for tau homeostasis, and they complement previous studies on protein subnetworks responsible for protein homeostasis in different neurodegenerative disorders 34 . We anticipate that further demonstrations of the complex and highly regulated interactions between different protein homeostasis components will reveal more determinants of the vulnerability of specific neuron types. Lastly, our findings emphasize the importance of pursuing novel therapeutic strategies of enhancing natural defense mechanisms that maintain our proteome in a soluble state 35, 36 and the use of protein homeostasis enhancing therapeutics, especially if they can be designed to target specific cell types, such as vulnerable EX neurons.
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Methods
Reagents. Human conformation-dependent tau (MC1) and human/murine phospho-tau pSer396/ Ser404 (PHF1) monoclonal antibodies were provided by P. Davies. Mouse anti-phosphorylated tau Ser262 and/or Ser356 (12E8) antibodies 37 were provided by P. Dolan. Human/murine phospho-tau pSer202/ Thr205 (AT8, Cat# MN1020) and pThr212/Ser214 (AT100, Cat# MN1060) monoclonal antibodies, rabbit anti-phospho-tau pSer422 (pS422, Cat# 44-764 G), and parvalbumin (PVALB, Cat# PA5-18389) polyclonal antibodies, Alexa Fluor dye-labeled cross-absorbed goat and donkey secondary antibodies (Cat# A-11029, A-11037, A-11007, A-11058, and A-21202), SlowFade gold (Cat# S36937), and ProLong gold (Cat# P36934) antifade reagents were purchased from Thermo Fisher Scientific. Rabbit anti-TBR1 (Cat# ab31940) and SATB2 (Cat# ab92446) polyclonal antibodies were purchased from Abcam. Rat anti-somatostatin (SST; Cat# MAB354) and mouse anti-NeuN (Cat# MAB377) monoclonal antibody and goat anti-GAD1 (Cat# AF2086) polyclonal antibody were purchased from Millipore and R&D Systems, respectively. Rabbit anti-calretinin (CALB2; Cat# 7697), IBA-1 (Cat# 019-19741), and GFAP (Cat# G9269) polyclonal antibodies were purchased from Swant, Wako, and Sigma-Aldrich, respectively. RNAscope Multiplex Fluorescence Kit (Cat #320851) and human-specific RNA probes, including SLC17A7 (Cat# 415611 or 415611-C2), GAD1 (Cat# 404031-C3), MAPT (Cat# 472621), MAPK1 (Cat# 470741), FKBP5 (Cat# 481101), and ENC1 (custom probe), were purchased from Advanced Cell Diagnostics. TrueBlack lipofuscin autofluorescence quencher (Cat# 23007) was purchased from Biotium. Lentiviral vectors FG12-scramble and FG12-shBAG3 were prepared as previously described 21 , and the GFP in these vectors was removed by cutting with AgeI and BsrGI followed by fill-in of 5′ overhangs and re-ligation. The shRNA-resistant BAG3 in FigB was made by changing the underlined bases of the shRNA target sequence (AAG GTT CAG ACC ATC TTG GAA), which does not change the amino acid but results in an shRNA-resistant BAG3 (AAA GTA CAA ACT ATC TTG GAA). Viral packaging vectors psPAX2 and VSVG were provided by C. Pröschel. Tau RD-P301S-YFP (aa 244-372 of the 441 amino acids in full-length tau; mutations P301S) and the clone 9 (DS9) tau seeds (provided by M. Diamond) were prepared as previously described 38 . Rabbit anti-TBR1 (Cat# 20932-1-AP) and rabbit anti-BAG3 (Cat# 10599-1-AP) polyclonal antibody were purchased from Proteintech Group. Unless otherwise noted, all other reagents were purchased from Fisher Scientific or Thermo Fisher Scientific.
Animals.
We previously generated a tau transgenic mouse model known as EC-tau 20 by crossing the neuropsin-tTA activator line with a tetracycline-inducible tau P301L responder line. The F1 offspring (both males and females at 22 and 30+ months old, strain FVB/N:C57BL/6) were used as experimental animals. All animals were maintained on a 12-h light/dark cycle with food and water provided ad libitum. All animal experiments were performed in accordance with national guidelines (National Institutes of Health) and approved by the Institutional Animal Care and Use Committee of Columbia University. Mice were transcardially perfused with phosphate-buffered saline (PBS), brains were harvested and dropfixed in 4% paraformaldehyde (PFA; Cat# 15710, Electron Microscopy Sciences) in PBS at 4 °C overnight, and free-floating sections (35 µ m) were prepared as previously described 39 . Table 4 . These specimens were obtained by consent at autopsy and have been deidentified and are IRB exempt so as to protect the identity of each patient. Frozen sections (10 µ m) were cut from frozen blocks under RNase-free conditions by the Histology Service at Columbia University Medical Center.
Human brain tissues.

Immunofluorescence staining on mouse and human brain sections.
Immunostaining was performed as previously described with a few modifications for human brain sections 39 . Free-floating brain sections from EC-tau and agematched nontransgenic (WT) mice at 22 and 30+ months as well as from human brains were subjected to antigen retrieval by 10-min incubation in 10 mM sodium citrate (pH6.0, 95 °C). After blocking, the sections were stained with TBR1 (1:250), SATB2 (1:250), PVALB (1:1,000), SST (1:100), or CALB2 (1:1,000) antibodies in the blocking solution on the first day, followed by incubation with MC1 (1:750), AT8 (1:500), PHF1 (1:500), or pS422 (1:250) tau antibodies on the next day. Freshfrozen human brain sections were air-dried and fixed with cold acetone for 10 min at -20 °C. They were then incubated with TBR1 (1:250), SATB2 (1:250), GAD1 (1:100) or GFAP (1:2,500) antibodies in blocking solution, followed by incubation with AT8 (1:500), PHF1 (1:500), pS422 (1:250) or AT100 (1:500) tau antibodies on the next day. Human FFPE sections were deparaffinized and rehydrated before the same procedure of antigen retrieval described above, followed by sequential immunolabeling with TBR1 (1:250), SATB2 (1:250) or IBA-1 (1:500) antibodies and MC1 or AT8 tau antibodies (1:500). We chose the sequential staining instead of the more common co-staining because we found substantial co-localization artifacts of tau and neuronal markers, especially SST. After three washes with phosphate-buffered saline with Tween 20 solution (PBST), the sections were incubated with appropriate Alexa Fluor dye-labeled cross-absorbed goat or donkey secondary antibodies (1:1,000) for 2 h (mouse sections) or 3 h (human sections) at 20-25 °C. Following three washes with phosphate buffered saline solution (PBS), autofluorescence was quenched with 0.3% Sudan black in 70% ethanol for 6 min (mouse sections) or 12 min (human sections) at room temperature. The nuclei were stained with 5 mg/mL Hoechst33342 (Cat# 14533, Sigma-Aldrich) in PBST for 10 min at room temperature. Following three washes with PBS, sections were mounted on slides using SlowFade gold antifade reagent and imaged using confocal laser scanning microscopy (LSM800, Zeiss) via z-stack to assess co-localization. A fluorescence microscope (BX51, Olympus) was used for quantitation. The numbers of neuronal marker-positive, MC1 + , and co-stained neurons in layers II-IV of the MEC, PRH, and NC were quantified manually using ImageJ software.
Co-staining GAD1 (1:100), NeuN (1:250), and BAG3 (1:100) on human brain frozen sections (BA9 region) was performed as described above. Stained sections were imaged using confocal laser scanning microscopy via z-stack. We used ImageJ to open the original CZI files, customize the channel colors, set measurements in analysis (mean intensity and area), and select different types of neurons by drawing a circle around the cell. The 'measure' function generated the analysis. 25 . A differential expression analysis was performed on both datasets. Raw data were log-normalized, and then z-score normalization was performed for all genes across the samples to enable direct comparisons between them. Genes with replicates were first z-scored and then the averaged across different samples. For the DroNc-Seq dataset, the matrix of transcript reads had many zero entries within the transcriptome. To avoid biases in the analysis and reduce the amount of noise, the bottom 5% lowest-quality samples (samples with fewest reads across the transcriptome) were discarded, as they were considered to have been damaged during the experimental procedure. A ∆ score 19 for the genes corresponding to each subproteome was calculated as IN (GAD1, GAD1, SLC32A1 ) genes was greater than the maximum expression of EX (SLC17A6, SLC17A7) or non-neuronal (OLIG1, GJA1, XDH, CTSS, MY19) genes. All remaining cells were classified as nonneuronal 40 . For the SNS dataset, we combined brain regions BA21, BA22, BA10, and BA41 and considered them to be a region affected early in AD (low Braak stage). BA17 was considered to be a region affected later in AD (higher Braak stage) region. For the DroNc-Seq dataset, hippocampus (HP) was considered to be an early-affected region, while the prefrontal cortex (PFC/BA9) was considered to be a later-affected region 4 .
Statistical analysis of the RNA-seq results. The statistical significance of the results in Figs. 3 and 4 was studied by creating a null model for each subproteome under scrutiny. This approach enabled us to assess the statistical significance of a given result and consists of the comparison between a specific value and a distribution of values obtained from multiple random samples of the same size as the reference sample. Each delta-score ∆ {s} associated with a subproteome {s} containing n s genes, obtained as a global average of the expression values of the group of genes of interest, was directly compared to a distribution of ∆ scores, obtained by sampling the transcriptome of reference multiple times and by creating multiple random subproteomes of the same size n s as the reference subproteome. The P value was then the probability of obtaining a value more extreme than the empirical one, using the random distribution as a reference.
Weighted gene co-expression network analysis. Weighted gene co-expression network analysis is a data mining method that allows the quantification and interpretation of correlations between variables. In biology, this approach is widely used to study the covariation of genes and proteins across different samples and conditions (different cell types in our analysis). It is based on the definition of a similarity measure, the Pearson's correlation coefficient in our case, which serves as a parameter to build the topology of the network. The Pearson's correlation coefficient is defined as 
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Data analysis
Excel, ImageJ, ZEN 2 (blue edition), Python2.7 and Graphpad Prism 5.0 softwares were used.
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